Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312517 · ClinicalTrials.gov registry record · Phase 4
Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
A Phase 4 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT03312517 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 12 participants.
The verdict
NCT03312517, a Phase 4 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (responsivity) of Belsomra 10 mg and 20 mg to Placebo in non-elderly Insomniacs
Interventions
- DRUG Suvorexant 10 mg
- DRUG Placebo oral capsule
- DRUG Suvorexant 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-04-15 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03312517
The ClinicalTrials.gov registry entry for NCT03312517 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Suvorexant 10 mg is the first listed.
NCT03312517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03312517 about?
NCT03312517 is a clinical study titled "Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs". Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (responsivity) of Belsomra 10 mg and 20 mg to Placebo in non-elderly Insomniacs
What is the current status of trial NCT03312517?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2018-04-15. Estimated completion is 2018-10-25.
What interventions are being tested in trial NCT03312517?
The interventions under investigation include: Suvorexant 10 mg (DRUG), Placebo oral capsule (DRUG), Suvorexant 20 mg (DRUG).
Who is sponsoring clinical trial NCT03312517?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.